Objective: To estimate the health care expenditure and productivity losses due to smoking. Design: A retrospective cohort study of a random population sample of 5,247 men aged 25-59 years from the provinces of Kuopio and North Karelia in eastern Finland. Subjects initially surveyed in 1972 were linked to a set of national registers through their social security identification numbers and followed for 19 years. The difference in the number of life years and work years lost, the costs of drugs and hospitalization, and the value of productivity lost due to disability and premature mortality between smokers, former smokers and never-smokers was analysed. Results: The difference in mean life expectancy between current smokers and never-smokers was 3.0 years, and the difference in mean lost work time was 2.6 years over the 19 years of follow-up. Between current smokers and former smokers, the difference in mean life expectancy was 1.8 years, and the difference in mean lost work time was 1.6 years. The mean difference between a current smoker and a never-smoker in health service costs was € 2,900, and the difference in mean total costs was € 69,300 (an increase of 86%). No difference in mean health care costs between current smokers and former-smokers was found, while the difference in mean total cost was € 44,000. Conclusions: Smokers incurred excess costs in terms of both direct health care expenditure and indirect productivity losses in comparison to the never-smoking population. Most importantly, quitting smoking could save at least 60% of the losses related to excess mortality and disability of smokers.
factor behind several major chronic diseases, notably cardiovascular diseases, cancers (especially lung cancer), and diseases of the respiratory system. The economic issues of smoking have been studied from various viewpoints, for various purposes, and with varying methods. Some studies have concentrated on the impact of smoking on health service expenditure only, 1,2 while others have included productivity losses (indirect costs) as well. [3] [4] [5] Another viewpoint is to assess the financial externality of the smoking habit. [6] [7] [8] Under the cost-of-illness methodology two alternative approaches are available. The prevalence-based approach provides estimates of a disease's cost impact over a defined time period (usually a year). The other approach is based on the incidence of a disease, and provides estimates of the costs over its whole life cycle. The incidence-based approach is considered to be more valid for estimating the benefits of quitting, since reducing smoking in the population affects the likelihood of the onset of certain diseases. The incidence method suffers from some practical problems. Data on the costs borne throughout the course of long-standing diseases are extremely difficult and costly to obtain. Therefore, the models usually include a limited number of possible diagnoses 3, 1 and/or use cross-sectional survey data to generate lifetime health service consumption profiles by smoking status. 3, 8 It is common to make use of rather strong assumptions, for instance, to assume that the association between smoking and medical care utilization follows that of smoking and mortality. 1 Also, due to lack of information on concurrent incidence, simply adding care costs of several smoking-related diseases may lead to double counting. 8 This study introduces a new follow-up approach for estimating direct and indirect costs of smoking and the potential benefits of quitting. The analysis is based on extraordinary data from a random population sample of individuals who have been followed for their actual consumption of health services and time lost from work over a 19-year period. Thus, we can overcome the problems associated with the assessment of the disease incidence, determining the incidence-based costs for a number of diagnoses, and the competing risks. EUROPEAN JOURNAL OF PUBLIC HEALTH 2002; 12: 145-151 
DATA AND METHODS
The data on smoking status and background variables were obtained from a 1972 population health examination survey conducted in two eastern Finnish provinces, Kuopio and North Karelia. The survey data of almost 11,000 subjects aged 25 to 59 years was linked with the major national registers that contained information concerning morbidity-and mortality-related cost events over the 19-year follow-up period (1972) (1973) (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) . Study subjects were classified into three categories according to smoking status at the time of the baseline survey: current smokers, former smokers, and neversmokers. The difference between current smokers and never-smokers describes costs incurred by the currently smoking population in excess of those who have never smoked. The difference between current smokers and former smokers describes the average gains experienced by those who actually had quit (at least six months before the survey) in comparison to those who continued smoking. For the sake of simplicity, and in line with Oster et al., 3, 4 the expressions 'cost of smoking' and 'benefits of quitting' are used in referring to the respective differences. It is acknowledged that the entire difference between the groups is not attributable to smoking habit alone, since smokers also differ from non-smokers by other characteristics that are likely to incur excess costs over lifetime. 1 Hence, our findings are based on the observation of experiences of the population of smokers and nonsmokers as it actually consisted in 1972. Women are excluded due to an inadequate number reporting current smoking (19%) and especially former smoking (8%) in 1972.
Direct costs
Two components of direct health care costs were included in the analysis: costs of hospitalization and costs of major drugs. Thus, all direct costs are not included, but the cost of hospital care alone accounted for 44.4% to 50.8% of the total health care expenditure in Finland over the study period. The most important of the lacking cost items is the cost of primary care services, for which no national registers are currently available. Details, including discharge diagnosis and type of hospital, of all hospitalizations for each study subject was obtained from the Hospital Discharge Register (HDR) covering all Finnish hospitals. Costs are not recorded in HDR, and no diagnosis-related cost information was available for the study period. The mean cost per bed-day was obtained for university hospitals, central hospitals, other general hospitals, mental care institutions, and health centre wards, which are known to differ by the resource intensity of treatments available, and used as a unit cost for all treatments in a particular type of hospital. Practically all prescription drugs used for treating major chronic diseases are refundable through the National Sickness Insurance scheme (NSI), administered by the Social Insurance Institution (SII). The registers of SII contain information on type of drug, dates of approval and discontinuation of persons' eligibility for reimbursements.
The time of eligibility was valued using the average cost for a whole year of drug therapy for each disease. The number of days the person was entitled to refunds for medication was reduced by the number of overlapping days spent hospitalized. During the hospitalization period the drugs are usually provided by the hospital, and hence their costs are, in principle, included in the hospitalization costs.
Indirect costs
Estimation of indirect costs-of-illness is based on the human capital method, which derives the values of the loss of health and livelihood from the losses in potential earnings. 9, 10 Time lost from work, by diagnosis, was derived from the national Cause of Death Register and the SII's registers on disability pensions and sickness absence. The data on sickness absence was available only since 1978, hence the cost of disability is underestimated in our calculation. Moreover, the sickness absence periods shorter than one week were omitted since they are not covered by the NSI. The expected number of work years lost due to premature mortality was estimated by accumulating the general survival probabilities for each year of life from the age of death until the age of 65, after which no loss of productivity was expected. The monetary value for lost working time was obtained by dividing the gross national product (GNP) by the number of working-age inhabitants, hence effectively adjusting for the rate of unemployment and labour force participation. 11 The expected value of lost production due to premature deaths was adjusted for a 2% annual increase of labour productivity. The difference in life years lost was also analysed. It is a common outcome measure in cost-effectiveness studies, and hence, enables wider comparison of results. The estimation of expected number of life years lost was done as in case of lost working years due to mortality, but setting the absolute limit for survival to the age of 99. The social security identification numbers appear in all data sources, which enables one to produce personal cost record for each individual. Cost events were measured separately for each year of the follow-up (1972) (1973) (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) , valued using unit costs determined annually in current prices, adjusted for inflation, 12 discounted (at rates of 0% and 5%) to the baseline year of 1972, and finally the individual's annual costs was summed up to a single figure. Costs are reported in euro (€ 1=FIM5,94573) at 1999 prices. Mean costs were calculated by smoking status in five-year age groups (table 1) . The difference between the means was considered statistically significant if t-test probability level was less than 0.05. Analysis of variance was used to examine whether the cost difference by smoking status varied across the age categories.
RESULTS
On average, male smokers lost 3.0 more years of life during the 19-year follow-up than men who had never smoked in their lives (column 'C-N', table 2). The difference between current smokers and former smokers was 1.8 years (column 'C-F', table 2). This implies that 60% of the life years lost by smokers can be saved by quitting. In terms of lost working time, current smokers lost 2.6 more years than never-smokers, and 1.6 years was the potential gain from quitting. Half of the difference in life expectancy (1.5 years) between smokers and never-smokers materialized before the common age of retirement. An even bigger share (>70%) of the gain in life expectancy due to quitting was potentially productive years. The number of work years lost due to disability included both sick leaves and disability pensions. Disabilities were found to have an almost equally important effect on lost working time (1.1 years) as early deaths. In terms of disability, however, no statistically significant gains (p=0.0836) were associated with smoking cessation. Table 3 shows the results of the cost analysis. Current smokers did not incur statistically significant excess cost of drugs compared to never-smokers, and current smokers appeared to consume fewer drugs than former smokers did over the 19-year study period. The cost of hospital utilization by smokers was 50% (€ 2,900) greater than by neversmokers during the follow-up period. No statistically significant difference was found between current smokers and former smokers. The difference in the cost of lost productivity between current smokers and never-smokers was approximately € 66,000, of which 58% was due to early mortality and the rest due to temporary or permanent disability. The difference in mortality-related production losses between current smokers and former smokers was € 36,000. The benefits of quitting arising from a decrease in disability Cost of smoking and benefits of quitting were worth € 8,000, but the difference was not statistically significant (p=0.067). The total cost difference between current smokers and never-smokers was € 69,000 undiscounted, and € 38,000 discounted. The potential benefit of quitting was € 44,000 undiscounted, and € 20,000 discounted.
Analysis of variance (ANOVA) indicated that the difference in the lost life expectancy between current smokers and never-smokers was statistically significantly (p=0.040) affected by age (table 4) . The difference in life expectancy appeared to be highest in age groups 40 to 44 and 45 to 49 years. In older age groups the increase in never-smokers mortality and decline in overall life expectancy (competing causes) results in a diminishing difference between the two groups. The difference in the cost of drugs by smoking status was also clearly affected by age (table 5 ). An overall trend seemed to be that the excess costs of current smokers in younger age groups turned into excess costs of neversmokers in ages 45 to 49 and older. Former smokers' drug costs were higher than current smokers' costs in all age groups except one (30 to 34), and the (negative) difference increased by age group.
DISCUSSION
The evidence concerning the excess costs of smoking is convincing. Mean disease-related costs recorded in this study during the 19-year follow-up were on average 86% higher among men who smoked regularly than among those who had never smoked. The value of production losses due to premature deaths and disability together accounted for 96% of the total costs. This proportion is somewhat higher than in some earlier studies, which is explained mainly by the lack of data on primary care services. For example, the corresponding proportion in Pekurinen's study was around 80%. 5,p.154 The large share of indirect costs describes the disabling and fatal nature of the smoking habit. The design of this study allowed assessment of the costs that a current smoker (male) is expected to impose on the health care system and society in general over the next 19 years of his life. The fact that approximately half of those who were current smokers in 1972 quit during the 19-year follow-up makes the estimates rather conservative. The status of never-smokers is not likely to have changed, since it is rather uncommon to commence regular smoking after 25 years of age if one had never smoked earlier in life. 13 Assessing the potential benefits of quitting is a more complicated issue. It is, however, clear that reduction of premature mortality is the most important source of the benefits of quitting accounting for about 80% of the potential monetary gains. Moreover, the analysis suggests that almost 90% (table 2, € 35,700/€ 40,500) of the lost productive value due to excess mortality by smokers could be saved by quitting smoking. An unexpected finding in the study was that smoking cessation was not associated with any significant savings in the cost of hospital care. Moreover, the estimated cost of drugs was higher among former smokers than among those who smoked regularly at the time of the survey. The potential explanations of this finding arise from three sources. First, the fact that former smokers are more likely to start smoking than their never-smoker peers coupled with the high rate of cessation by current smokers after the survey makes our estimates for benefits of quitting even more conservative than our estimates for costs of smoking. The lack of longitudinal control on smoking status, however, is not likely to explain the whole phenomenon, especially the increase in drug costs. Second, an uncontrolled factor may have influenced both individuals' decision to quit and their health service utilization. The most likely candidate is a smoking-related disease, for which our analyses seem to offer some support. Former smokers were more likely to have had at least one hospital admission during the follow-up than current smokers. Also, the former smokers had spent more days in hospital due to diseases of the respiratory system (ICD codes 460-519) than did current smokers, even though the difference was not statistically significant. So, instead of or in addition to the pure benefits of quitting, the result may reflect the known fact that long-standing disease is a strong incentive to quit smoking. 14 Third, it has been argued that the savings in the treatment of tobacco-related diseases would be outweighed by the health service consumption of the increased population in the older age groups. 1 This hypothesis was not, in general, confirmed by our analysis. The difference in health service costs between current smokers and neversmokers was clearly in favour of never-smokers (table 3) , despite a relatively greater difference in life expectancy (table 2) . The argument may, however, be valid with former smokers, since quitting results in significant gains in life expectancy but the annual health care costs among former smokers remain at a relatively high level. The higher health service use of former smokers than current smokers has also been reported by Manning et al. 8, pp.73, 74 The estimates of direct 'costs of smoking' and 'benefits of quitting' were generally lower than in earlier studies on this topic. 2, 4 An exception was the Swiss study, 1 according to which average smokers consumed less health care resources over their lifetime than non-smokers. Present estimates of indirect costs, however, were somewhat higher than those estimated elsewhere. 4 Lifeexpectancy gains from quitting were compared to the corresponding estimates used in the cost-effectiveness study by Oster et al. 15 in 5-year age groups among persons aged 35 to 59. The undiscounted number of life years gained in the age group 35 to 39 years was approximately double in the US study compared to current estimates (5.08 vs. 2.54 years), but in the age group 55 to 59 years the two estimates approached each other (2.60 vs. 2.43 years, respectively). The discounted (5%) estimates used by Oster et al. 15 were 0.99, 1.07, 1.10, 1.07, and 0.97 years from the youngest to the oldest age group, while current estimates were 0.90, 1.18, 1.06, 1.09, and 1.15 years, respectively. This suggests that in younger age groups costs are likely to be underestimated due to limited follow-up time, and that discounting reduces the extent of this bias. The human capital valuation principle derives the value of lost years of life from the productive value of individuals' time. [16] [17] [18] It is emphasized that the value given to indirect costs should be understood as an accounting value for potentially lost production, without any implication to the value of life per se. Also, the use of different valuation methods, such as the so-called friction cost approach, 19,20 may result in a different level of monetary estimates of productivity loss. Koopmanchap et al. 20 suggested that using the friction cost method, the total indirect cost of diseases could be only about 10% of that generated by the human capital approach. Although, the absolute magnitude of indirect cost may be subject to debate the relative differences between the smoking categories should be less sensitive to the method of valuation. It is acknowledged that one should be aware of the methodological dispute when drawing conclusions based on the absolute level of the indirect costs. The human capital method is still by far the most commonly used valuation method. The design of the present study does not allow separation of the costs incurred by cigarette smoking as such from the costs related to the other characteristics and behaviours by which an average smoker may differ from an average non-smoker. Since smoking is associated with many other poor health habits the entire cost difference between smokers and non-smokers is not due to smoking. Also, poor health habits are associated with low socioeconomic status 21 and hence with less favourable family background, and economic and environmental conditions. Earlier analyses on this study population found that smokers in 1972 had lower blood pressure but higher serum cholesterol concentration, 22,23 though more recently all three were found to be in positive association, and, in spite of decreasing prevalence over time, smoking has been found to be increasingly clustered with the other two. 23 Controlling for all sources of heterogeneity between smoking and non-smoking populations may not be possible, and since the causal structure of the statistical associations is not well established it could even lead to underestimation of the effect of smoking. It is believed that smoking is responsible for most of the difference found in this present study. Based on the major prospective studies Leu and Shaub 1 assessed that 65% would be a conservative estimate of the excess mortality of smokers attributable to smoking. Most of the studies assessing the benefits of prevention usually deal with a middle-aged population and often have a relatively short-term perspective (five to ten years). For public policy, however, it is important to have a full picture, i.e. to understand the long-term impact of risk factors like smoking on health outcomes and related costs. Although this study did not follow the subjects from birth to death, it gives an unusually broad picture. The study subjects, initially from 25 to 59 years of age, were followed for 19 years. Thus, the oldest people followed were up to 78 years of age, which starts to provide relevant information on experiences among the older population.
Cost of smoking and benefits of quitting

CONCLUSIONS
Smokers experienced large excess losses in life expectancy (3.0 years) and in potential working time (2.6 years) in comparison with non-smokers during the 19-year followup period. Smokers also incur excess costs up to more than 190% (€ 40,500) depending on the cost item. Those who had quit seem to gain considerably in terms of mortalityrelated outcomes. In particular, the expected number of working years lost by former smokers (1.0 years) was relatively close to that of never-smokers (0.8 years).
Disability-related benefits of quitting were not found to be statistically significant, nor were savings in health care costs.
